Vaxart (VXRT) News Today $0.45 +0.02 (+4.92%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.44 0.00 (-1.05%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13May 2 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?May 2 at 4:43 AM | marketbeat.comVaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine CandidateApril 30, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - Should You Sell?April 24, 2025 | marketbeat.comVaxartto Present at World Vaccine Congress Washington 2025 on April 23April 16, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - Here's What HappenedVaxart (NASDAQ:VXRT) Shares Pass Below 200 Day Moving Average - Should You Sell?April 10, 2025 | marketbeat.comB. Riley Issues Positive Outlook for Vaxart EarningsVaxart, Inc. (NASDAQ:VXRT - Free Report) - B. Riley lifted their Q1 2025 earnings estimates for Vaxart in a research note issued to investors on Wednesday, March 26th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings of ($0.07) per share for the quarteMarch 31, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Price Target Lowered to $2.00 at B. RileyB. Riley cut their target price on Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a report on Thursday.March 28, 2025 | marketbeat.comVaxart price target lowered to $2 from $2.50 at B. RileyMarch 27, 2025 | markets.businessinsider.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | insidermonkey.comVaxart (NASDAQ:VXRT) Announces Earnings Results, Beats Estimates By $0.05 EPSVaxart (NASDAQ:VXRT - Get Free Report) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.05. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%.March 21, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Issues Earnings ResultsVaxart (NASDAQ:VXRT - Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.March 21, 2025 | marketbeat.comVaxart, Inc. (VXRT) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comVaxart Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 20, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Short Interest UpdateVaxart, Inc. (NASDAQ:VXRT - Get Free Report) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 13,280,000 shares, an increase of 17.0% from the February 13th total of 11,350,000 shares. Based on an average daily volume of 1,960,000 shares, the short-interest ratio is presently 6.8 days. Currently, 6.0% of the shares of the stock are sold short.March 19, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average - Here's WhyMarch 14, 2025 | marketbeat.comVaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20March 14, 2025 | markets.businessinsider.comVaxart announces trial initiation of norovirus oral pill vaccine candidateMarch 11, 2025 | markets.businessinsider.comVaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine CandidateMarch 11, 2025 | globenewswire.comVaxart (VXRT) to Release Earnings on ThursdayVaxart (NASDAQ:VXRT) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comVaxart (VXRT) Projected to Post Quarterly Earnings on ThursdayVaxart (NASDAQ:VXRT) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comVaxart announces norovirus vaccine candidate trial data publishedMarch 5, 2025 | markets.businessinsider.comVaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly AdultsMarch 5, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average - Should You Sell?March 4, 2025 | marketbeat.comMultimillion-dollar Biden-era COVID-19 vax project halted by Trump’s HHSFebruary 26, 2025 | msn.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving Average - What's Next?February 13, 2025 | marketbeat.comVaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of DirectorsJanuary 28, 2025 | markets.businessinsider.comVaxart appoints Kevin Finney to board of directorsJanuary 28, 2025 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average - Time to Sell?Vaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Should You Sell?January 17, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average - Here's WhyJanuary 16, 2025 | marketbeat.comVaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Passes Below 200 Day Moving Average - Here's What HappenedJanuary 16, 2025 | marketbeat.comVaxart highlights progress of COVID-19, norovirus, influenza programsJanuary 14, 2025 | markets.businessinsider.comVaxart Announces Favorable DSMB Review To Continue COVID-19 Phase 2b Trial; Stock UpJanuary 14, 2025 | markets.businessinsider.comVaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical TrialJanuary 13, 2025 | globenewswire.comVaxart project agreement change ups funding for oral COVID vaccine candidateDecember 28, 2024 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving Average - What's Next?Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200 Day Moving Average - Here's WhyDecember 21, 2024 | marketbeat.comVaxart (NASDAQ:VXRT) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average - Time to Sell?December 13, 2024 | marketbeat.comVaxart completes enrollment in Phase 2b study evaluating its COVID-19 pillDecember 3, 2024 | markets.businessinsider.comVaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine CandidateDecember 2, 2024 | globenewswire.comSio Capital Management LLC Decreases Holdings in Vaxart, Inc. (NASDAQ:VXRT)Sio Capital Management LLC lowered its holdings in Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 7.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,608,244 shares of the biotechnology compNovember 29, 2024 | marketbeat.comB. Riley Forecasts Vaxart's FY2024 Earnings (NASDAQ:VXRT)Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Investment analysts at B. Riley raised their FY2024 earnings per share estimates for shares of Vaxart in a research note issued to investors on Monday, November 18th. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will post earnNovember 21, 2024 | marketbeat.comFY2027 Earnings Estimate for Vaxart Issued By B. RileyVaxart, Inc. (NASDAQ:VXRT - Free Report) - Stock analysts at B. Riley issued their FY2027 earnings estimates for shares of Vaxart in a research report issued to clients and investors on Monday, November 18th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will earn $0.09 perNovember 20, 2024 | marketbeat.comVaxart reports inducement grants under Nasdaq listing ruleNovember 20, 2024 | markets.businessinsider.comVaxart’s Promising Advancements in Oral Vaccine Development and Norovirus Program Drive Buy RatingNovember 19, 2024 | markets.businessinsider.comVaxart (VXRT) Receives a Buy from OppenheimerNovember 14, 2024 | markets.businessinsider.comVaxart’s Q3 2024: Progress in Oral Vaccine DevelopmentNovember 14, 2024 | markets.businessinsider.comVaxart, Inc. (VXRT) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comVaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | globenewswire.comVaxart (VXRT) to Release Earnings on WednesdayVaxart (NASDAQ:VXRT) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 8, 2024 | marketbeat.com Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Media Mentions By Week VXRT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VXRT News Sentiment▼0.000.73▲Average Medical News Sentiment VXRT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VXRT Articles This Week▼31▲VXRT Articles Average Week Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Erasca News Today Sana Biotechnology News Today Zevra Therapeutics News Today Altimmune News Today SNDL News Today Oruka Therapeutics News Today Kamada News Today Revance Therapeutics News Today Tectonic Therapeutic News Today Autolus Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VXRT) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VXRT Stock Free VXRT Stock Alerts